Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Processa PharmaceuticalsPCSA +2.85%29 3-Year EBITDA Growth Rate is 74.00% as of Mar. 2026, which is 325% above its 10-year median of 17.40. GuruFocus rates PCSA with a GF Scoreâ„¢ of 29/100. The stock has 1 warning sign investors should review. Among 1,137 Biotechnology companies, Processa Pharmaceuticals ranks better than 94.64% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 74.00% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 54.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Processa Pharmaceuticals was 74.00% per year. The lowest was -68.60% per year. And the median was 17.40% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Processa Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms
PCSA vs ELAB, MBIO, DRMA: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Processa Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Processa Pharmaceuticals 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Processa Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Processa Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 74.00% mean?
Processa Pharmaceuticals (PCSA) has a 3-Year EBITDA Growth Rate of 74.00% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Processa Pharmaceuticals and its competitors. This is 325% above median its historical median of 17.40. According to the industry distribution chart, Processa Pharmaceuticals ranks #61 out of 1137 companies in the Biotechnology industry, placing it in the top 5.4%.
Is Processa Pharmaceuticals' 3-Year EBITDA Growth Rate too high?
Processa Pharmaceuticals' current 3-Year EBITDA Growth Rate of 74.00% is 325% above median its 10-year median of 17.40. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.80. Processa Pharmaceuticals' value of 74.00% is 400% above this industry median. Based on the distribution chart, Processa Pharmaceuticals ranks #61 out of 1137 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Processa Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Processa Pharmaceuticals' 3-Year EBITDA Growth Rate compare to ELAB and MBIO?
According to the Biotechnology industry distribution chart, Processa Pharmaceuticals ranks #61 out of 1137 companies for 3-Year EBITDA Growth Rate. This places Processa Pharmaceuticals in the top 5% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.80. Processa Pharmaceuticals' value of 74.00% is 400% above this benchmark. While the company's 10-year median is 17.40 vs. the industry median of 14.80, Processa Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.80, based on 1,137 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Processa Pharmaceuticals's current 3-Year EBITDA Growth Rate of 74.00% is 400% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Processa Pharmaceuticals and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Processa Pharmaceuticals's current 3-Year EBITDA Growth Rate is 74.00%, which is 325% above median its own 10-year median of 17.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Processa Pharmaceuticals stock overvalued right now?
Processa Pharmaceuticals (PCSA) has a current 3-Year EBITDA Growth Rate of 74.00%. The current 3-Year EBITDA Growth Rate is 74.00%, which is 325% above median its 10-year median of 17.40 and 400% above the Biotechnology industry median of 14.80. Processa Pharmaceuticals' overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Processa Pharmaceuticals (PCSA), the current 3-Year EBITDA Growth Rate is 74.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.
29GF Score
Get the complete analysis for PCSA
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PCSA has been successfully added to your 
